Media mentions and company announcements
Dedicated to treating substance use and mental health disorders, Affect Therapeutics Raises $26 Million Series B to Scale an AI-Driven Operating System Contingency-management–powered, payer-inclusive virtual clinic—now in 20 U.S. states—combines therapy, medications, and real-time clinical decision support to engage hard-to-treat populations McLean, VA — September 23, 2025 — Dedicated to treating substance use and mental…
read moreAffect Expands Into Mental Health Treatment Services Affect Therapeutics, the leading digital health provider for addiction recovery, is expanding its services to include comprehensive mental health care — starting in Ohio, with additional states to follow soon. This expansion marks a major step toward improving access to affordable, evidence-based care for people living with conditions…
read moreAffect Therapeutics Joins King County Integrated Care Network to Expand Access to Digital Substance Use Disorder Treatment Affect Therapeutics, the leading provider of fully virtual, evidence-based substance use disorder (SUD) treatment, is proud to announce its acceptance into the King County Integrated Care Network (KCICN), significantly expanding access to care for Medicaid beneficiaries in King…
read moreComing Soon A survey team from CARF International* will be visiting on September 26 to September 27. We invited the surveyors to evaluate how well we meet international standards for quality. The survey will tell us what we are doing well and ways we might improve. As a result of this survey, we may…
read moreJon Peeples, MD, Affect's Chief Medical Officer, talked to Morgan Gonzales of
read moreJoe Roberts of Health Tech World recently
read moreMultiple news stories have been published covering our recent announcement of our $16 million series A fundraising round. Here are a few: Fortune Magazine makes note of it in their
read moreMcLean, VA- July 12, 2023 – Affect Therapeutics (“Affect”), a company reimagining addiction treatment for the digital age, today announces a $16 million Series A led by TechBio-focused
read moreIn the United States, the prevalence of
read moreWe're thrilled to announce that, in recognition of our commitment to quality care delivery, Affect has received accreditation from
read more
